The company was founded in 2004 under the name Pharmalink AB and is based in Stockholm, Sweden.


  • 2017

    Pharmalink changes name to Calliditas Therapeutics

    Publication of results from Phase 2b study in The Lancet

    End-of-Phase 2 meetings with FDA and EMA

  • 2016

    Preparations for end-of-Phase 2 meetings with FDA and EMA

    Obtains orphan designation for Nefecon in Europe

    Invited to work with the Kidney Health Initiative (American Society of Nephrology) to identify surrogate endpoints in IgA nephropathy

    Publication of meta-analysis related to change in urine protein as a surrogate endpoint with regards to IgA nephropathy, Tufts Medical Center, 2016

  • 2015

    Receives financing from existing investors to progress clinical process towards Phase 3

    Announces initial results from Phase 2b trial and achieves the primary endpoint in a planned interim analysis

  • 2014

    Nefecon core patents are granted in the US, Europe, China and Hong Kong

  • 2013

    Receives financing for completion of Phase 2b trial from Investinor and existing investors

  • 2012

    Owners including Industrifonden and Bengt Julander finance the launch of the Phase 2b (NEFIGAN) trial

  • 2011

    Pharmalink gains exclusive rights to the formulation technology to develop and manufacture Nefecon

  • 2010

    Obtains US orphan designation for Nefecon

  • 2008

    Phase 2a trial is completed, with positive results

  • 2004

    Obtains access to TARGIT technology from West Pharmaceutical Services for specific delivery to ileocecal region

    Stiftelsen Industrifonden invests in the company